Alexion Pharmaceuticals to Present Data on Soliris (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting

CHESHIRE, Conn., November 09, 2007 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab) as a treatment for patients with PNH, have been published by the American Society of Hematology (ASH). Abstracts will be presented at the 2007 ASH annual meeting that is being held December 8 to 11, 2007 at the Georgia World Congress Center in Atlanta.

The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The abstracts and presentation information can be accessed at the links provided below.

     -- "High Incidence of Progression to Chronic Renal Insufficiency in

        Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)" Dr. Peter

        Hillmen et al.

        http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416


     -- "Sustained Improvements in Transfusion Requirements, Fatigue and

        Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal

        Hemoglobinuria" Dr. Gerard Socie et al.

        http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204


     -- "Disease.Related Symptoms Reported across a Broad Population of

        Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr. Gabrielle

        Meyers et al.

        http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438.

The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.

     -- "Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria

        Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal

        Transfusion: Clinical Improvement with Eculizumab Therapy" Dr. Monica

        Bessler et al.

        http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302.


    [ALXN-G]

CONTACT: Irving Adler, Sr. Director, Corporate Communications of AlexionPharmaceuticals, Inc., +1-203-272-8210; or Media, Mark Marmur of Makovsky &Company, +1-212-508-9670; or Investors, Rhonda Chiger of Rx Communications,+1-917-322-2569

Ticker Symbol: (NASDAQ-NMS:ALXN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: November 2007

View comments

Hide
(web1)